• About Us
    • Overview
    • Education
    • Mission & History
    • Board of Directors
    • The Campus
    • Careers
  • Our Achievements
    • Overview
    • Cancer
    • Technology
    • Education
    • Our Planet
    • Health & Medicine
    • Physical World
  • Get Involved
    • Overview
    • Partners in Science
    • Estate & Planned Giving
    • Attend an Event
    • Gift Opportunities
  • News & Media
    • Overview
    • News & Media Archive
    • Coronavirus
    • Feature Stories
    • News Releases
    • In The News
    • Video Gallery
    • Ad Campaigns
    • Celebrating Great Minds
  • Blog
  • Contact
  • Donate
Donate
Donate
About Us tri
About Us Overview
  • Education
  • Mission & History
  • Board of Directors
  • The Campus
  • Careers
About Us

Founded in 1944, the American Committee for the Weizmann Institute of Science develops philanthropic support for the Weizmann Institute in Israel, and advances its mission of science for the benefit of humanity.

Our Achievements tri
Our Achievements Overview
  • Cancer
  • Technology
  • Education
  • Our Planet
  • Health & Medicine
  • Physical World
Our Achievements

The Weizmann Institute’s fundamental research has led to discoveries and applications with a major impact on the scientific community and on the quality of life for millions worldwide.

Get Involved tri
Get Involved Overview
  • Partners in Science
  • Estate & Planned Giving
  • Attend an Event
  • Gift Opportunities
Get Involved

Join a community of dedicated people who share the Weizmann Institute’s commitment to shaping a better world through science.

News & Media tri
News & Media Overview
  • News & Media Archive
  • Coronavirus
  • Feature Stories
  • News Releases
  • In The News
  • Video Gallery
  • Ad Campaigns
  • Celebrating Great Minds
News & Media

Learn about the Weizmann Institute’s latest groundbreaking discoveries and the American Committee’s activities across the country.

Blog tri
  • The Curiosity Review
Blog

Popular science for the curious-minded: The Curiosity Review brings discovery to life.

Contact

Search Results

  • SEARCH BY KEYWORD
  • SEARCH BY TAG
View Articles by Tag:
  • View Articles by Tag
  • Algorithims (6)
  • Alternative energy (27)
  • Alzheimers (44)
  • Archaeology (37)
  • Artificial intelligence (20)
  • Astrophysics (108)
  • Autism (22)
  • Awards (119)
  • Bacteria (107)
  • Behavior (9)
  • Biochemistry (101)
  • Biofuel (7)
  • Biology (309)
  • Biomolecular sciences (7)
  • Blood (43)
  • Brain (175)
  • Cancer (163)
  • Cancer treatment (127)
  • Central nervous system (9)
  • Chemistry (78)
  • Children (7)
  • Circadian clock (1)
  • Climate change (73)
  • Clinical trials (40)
  • Collaborations (19)
  • Community (279)
  • Computers (73)
  • Copaxone (12)
  • Coronavirus (7)
  • Culture (359)
  • Diabetes (32)
  • Earth (74)
  • Education (157)
  • Environment (92)
  • Enzymes (29)
  • Evolution (89)
  • Fertility (20)
  • Fungus (4)
  • Genetics (109)
  • Genomics (3)
  • Heart (5)
  • Heart disease (3)
  • Humanity (83)
  • Immune system (149)
  • Immunology (10)
  • Immunotherapy (34)
  • Inflammation (19)
  • Leadership (114)
  • Leukemia (12)
  • Materials (44)
  • Mathematics (62)
  • Medicine (84)
  • Memory (39)
  • Mental health (58)
  • Metabolism (51)
  • Microbiology (2)
  • Microbiome (10)
  • Molecular cell biology (9)
  • Molecular genetics (61)
  • Multiple sclerosis (12)
  • Nanoscience (33)
  • Nature (4)
  • Neurobiology (2)
  • Neuroscience (207)
  • Nutrition (72)
  • Optics (34)
  • Organs (11)
  • Parkinsons (11)
  • Personalized medicine (5)
  • Philanthropy (148)
  • Physics (139)
  • Plants (56)
  • Proteins (96)
  • Quantum computer (3)
  • Quantum physics (2)
  • Quantum theory (34)
  • Robots (8)
  • Security (21)
  • Senses (115)
  • Sensors (8)
  • Smoking (1)
  • Solar power (19)
  • Space (110)
  • Stem cells (49)
  • Technology (206)
  • Vaccine (40)
  • Virus (135)
  • Water (40)
  • Weather (1)
  • Women (115)
  • World hunger (17)
Filter by Time:
  • All
  • Past Day
  • Past Week
  • Past Month
  • Past Year
  • Past Three Years
Clear Filters

40 results for Clinical trials

Tiny Molecule Could Help Diagnose and Treat Mental Disorders
Tiny Molecule Could Help Diagnose and Treat Mental Disorders

https://www.weizmann-usa.org/news-media/news-releases/tiny-molecule-could-help-diagnose-and-treat-mental-disorders/

Jun 19, 2014... According the World Health Organization, mood disorders such as depression affect some 10% of the world’s population and are associated with a heavy burden of disease. That is why numerous scientists around the world have invested a great deal of effort in understanding these diseases. Yet the molecular and cellular mechanisms that underlie these problems are still only partly understood.
The existing antidepressants are not good enough: Some 60-70% of patients get no relief from them. For the other 30-40%, that relief is often incomplete, and they must take the drugs for a long period before feeling any effects. In addition, there are many side effects associated with the drugs. New and better drugs are clearly needed, an undertaking that requires, first and foremost, a better understanding of the processes and causes underlying the disorders.

TAGS: Medicine, Biochemistry, Molecular genetics, Mental health, Clinical trials

Using Basic Science to Advance Cancer Research
Using Basic Science to Advance Cancer Research

https://www.weizmann-usa.org/news-media/feature-stories/using-basic-science-to-advance-cancer-research/

Jan 05, 2016... The p53 gene is known as the “guardian of the genome” because it plays a key role in preventing healthy cells from turning cancerous. When p53 is mutated, however, it loses this function. This is significant, as more than 50 percent of all human cancers involve defects, mutations, or other alterations in the p53 gene.
“No other gene is implicated in so many cancers,” says Prof. Moshe Oren of the Weizmann Institute of Science’s Department of Molecular Cell Biology. “It makes you want to understand why.”

TAGS: Genetics, Cancer, Biology, Cancer treatment, Clinical trials

Revolutionary Therapy for Prostate Cancer Coming to Europe
Revolutionary Therapy for Prostate Cancer Coming to Europe

https://www.weizmann-usa.org/news-media/in-the-news/revolutionary-therapy-for-prostate-cancer-coming-to-europe/

Apr 11, 2016... Stop prostate cancer Photo via shutterstock
Tookad Soluble, a novel drug for prostate-cancer therapy delivered via injection and activated by laser light, was approved by Mexico’s health authority for early-stage prostate cancer earlier this year and now is undergoing advanced trials in Israel and Europe.
The revolutionary idea of photodynamic cancer therapy grew out of laboratory experiments at the Weizmann Institute of Science in Rehovot, Israel, by Prof. Yoram Salomon of the biological regulation department and Prof. Avigdor Scherz of the plant and environmental sciences department.

TAGS: Cancer, Cancer treatment, Clinical trials

Immunotherapy: Cancer Treatment Based on Weizmann Research is Saving Lives
Immunotherapy: Cancer Treatment Based on Weizmann Research is Saving Lives

https://www.weizmann-usa.org/news-media/feature-stories/immunotherapy-cancer-treatment-based-on-weizmann-research-is-saving-lives/

Mar 11, 2016... Maybe you heard about it on NPR. Or the BBC. Or your local paper or news station. The world paid attention to the news that a novel cancer treatment is sending blood cancer patients into "dramatic remission."
This is just the latest thrilling progress in the treatment, which uses a patient’s own immune system to defeat cancer. The Fred Hutchinson Cancer Center, which conducted the new trials, reports that "Twenty-seven out of 29 patients with an advanced blood cancer … experienced sustained remissions," and that "some of the patients in the trial, which began in 2013, were originally not expected to survive for more than a few months because their disease had previously relapsed or was resistant to other treatments," but "today, there is no sign of disease."

TAGS: Cancer, Cancer treatment, Immune system, Immunotherapy, Clinical trials, Leukemia

Coaxing the Immune System to Fight Cancer
Coaxing the Immune System to Fight Cancer

https://www.weizmann-usa.org/news-media/in-the-news/coaxing-the-immune-system-to-fight-cancer/

May 08, 2018... Image via Lightspring/Shutterstock.com
Immunotherapy was once the black sheep of cancer research. Originally conceived over a century ago, it aims to stimulate a patient’s own immune system to fight cancer. That’s a very different approach than chemotherapy, which essentially poisons tumors.
Early trials of immunotherapy in the 1900s and a second round of experiments in the 1980s caused toxic side effects. That led oncologists to dismiss this approach– until 2011, when a new immunotherapy treatment gave patients with metastatic melanoma years of tumor-free extra life.

TAGS: Cancer treatment, Immune system, Immunotherapy, Clinical trials

Research on Fertility Yields Unexpected Rewards
Research on Fertility Yields Unexpected Rewards

https://www.weizmann-usa.org/news-media/feature-stories/research-on-fertility-yields-unexpected-rewards/

Feb 16, 2011... When Prof. Nava Dekel of the Weizmann Institute of Science’s Department of Biological Regulation began studying a protein that plays a role in implanting fertilized eggs in the uterus, she had no idea it would lead to a discovery that is now helping couples struggling with infertility to have children.
For many years, Prof. Dekel focused her investigations on the mechanisms responsible for ovum (egg) development and embryo implantation. “But in science,” she says, “you can never decide ‘this is what I’m going to study for the rest of my life.’ You follow a path, and somewhere along the way you say, ‘Wow – there’s something interesting!’”

TAGS: Women, Biology, Clinical trials, Fertility

Melanoma/Skin Cancer Research at the Weizmann Institute of Science
Melanoma/Skin Cancer Research at the Weizmann Institute of Science

https://www.weizmann-usa.org/news-media/feature-stories/melanoma-skin-cancer-research-at-the-weizmann-institute-of-science/

May 03, 2012... Do you know that skin cancer is the most common form of cancer? And that it’s on the rise, with increased incidence over the last 30 years? In fact, the American Cancer Society estimates that, in 2013, almost 77,000 new melanomas will be diagnosed in the U.S. alone, and over 9,000 people will die of the disease.
While prevention and early screening are critical, fighting skin cancer once it develops is still a challenge. That’s why researchers at the Weizmann Institute of Science are attacking skin cancer and melanoma from a number of angles, including:

TAGS: Cancer, Cancer treatment, Clinical trials

Israeli Firm Offers Hope to Cancer Patients Beyond Standard Care
Israeli Firm Offers Hope to Cancer Patients Beyond Standard Care

https://www.weizmann-usa.org/news-media/in-the-news/israeli-firm-offers-hope-to-cancer-patients-beyond-standard-care/

Mar 24, 2019... Trial-In CEO Nir Erez. (photo credit: Courtesy)
Working in the field of oncology was a case of love at first sight for Weizmann Institute of Science graduate Nir Erez.
In 2003, after completing his Master’s degree, Erez joined pharma giant Roche Pharmaceuticals (Israel), which specializes in the development and marketing of cancer drugs. There, he worked alongside leading oncologists, learned of breakthrough cancer treatments and the development and types of the disease.

TAGS: Community, Cancer, Cancer treatment, Clinical trials

EMA Approves Steba’s Prostate Cancer Drug
EMA Approves Steba’s Prostate Cancer Drug

https://www.weizmann-usa.org/news-media/in-the-news/ema-approves-steba-s-prostate-cancer-drug/

Sep 25, 2017... Raphael and Fabrice Harari
The European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended by a majority of 29-2 the approval for marketing of the Tookad drug for treatment of prostate cancer developed by Israeli company Steba Biotech. Tookad is a complex treatment, in which the patient takes a drug, but the drug is activated only in the area of the tumor, through the skin. The product, developed by Professor Avigdor Scherz and Dr. Yoram Salomon of the Weizmann Institute of Science, has already been approved for marketing and sale in Israel and Mexico.

TAGS: Cancer, Cancer treatment, Clinical trials

European Study Green-Lights Israeli Test for Recurrence of Bladder Cancer
European Study Green-Lights Israeli Test for Recurrence of Bladder Cancer

https://www.weizmann-usa.org/news-media/in-the-news/european-study-green-lights-israeli-test-for-recurrence-of-bladder-cancer/

Jul 26, 2018... The Bladder EpiCheck diagnostic kit developed by Nucleix Ltd. (Courtesy)
Israeli startup Nucleix Ltd., a cancer detection screening company, has developed a urine test that it says can detect with high levels of accuracy the recurrence of bladder cancer in patients.
The company’s diagnostic kit studies a patient’s urine for changes in the DNA of the cells that could signal the repeated onset of cancer. “Ours is a noninvasive, very sensitive and cost effective liquid biopsy test,” said Dr. Opher Shapira, the CEO of Nucleix, in a phone interview.

TAGS: Cancer, Cancer treatment, Clinical trials

First 1 2 3 4 Last
Back Next
SHARE

Our Achievements

Learn more about remarkable Weizmann Institute achievements that are enhancing and transforming our lives.

Learn More

Support Our Flagship Projects

Help us accelerate exciting initiatives in three forward-looking fields: neuroscience, physics, and artificial intelligence.

Learn More

Newsletter

Get the latest news and breakthroughs from the Weizmann Institute of Science.

About Us
  • Education
  • Mission & History
  • Board of Directors
  • The Campus
  • Careers
Our Achievements
  • Cancer
  • Technology
  • Education
  • Our Planet
  • Health & Medicine
  • Physical World
Get Involved
  • Partners in Science
  • Estate & Planned Giving
  • Attend an Event
  • Gift Opportunities
News & Media Blog: Curiosity Review Donate Now Contact Us
Privacy Policy Gift Acceptance Policy Financial Information

©2023 American Committee for the Weizmann Institute of Science

Charity Navigator

FOR THE FOURTH CONSECUTIVE YEAR

Platinum Transparency 2023